NCT03657355View on ClinicalTrials.gov

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 7, 2018

Primary Completion Date

August 8, 2019

Study Completion Date

August 8, 2019

Conditions
Healthy Recreational Drug Users
Interventions
DRUG

ACT-541468

ACT-541468 will be administered as 50 mg tablets for oral use.

DRUG

Suvorexant

Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.

DRUG

Zolpidem

Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.

DRUG

Placebo

Matching-placebo will be used.

Trial Locations (2)

66212

Altasciences Clinical Kansas, Inc. (former Vince and Associates Clinical Research, Inc.), Overland Park

H3P 3P1

Altasciences Company Inc., Montreal

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT03657355 - Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users | Biotech Hunter | Biotech Hunter